Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

TRVI Trevi Therapeutics

Watchlist
1.750
-0.185-9.56%
Close 09/23 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
1.900
Open
1.900
Turnover
2.51M
Low
1.700
Pre Close
1.935
Volume
1.42M
Market Cap
77.12M
P/E(TTM)
Loss
52wk High
4.683
Shares
44.07M
P/E(Static)
Loss
52wk Low
0.460
Float Cap
37.63M
Bid/Ask %
50.00%
Historical High
10.620
Shs Float
21.50M
Volume Ratio
4.25
Historical Low
0.460
Dividend TTM
--
Div Yield TTM
--
P/B
1.27
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
6.62%
Amplitude
10.34%
Avg Price
1.764
Lot Size
1
Float Cap
37.63M
Bid/Ask %
50.00%
Historical High
10.620
Shs Float
21.50M
Volume Ratio
4.25
Historical Low
0.460
Dividend TTM
--
P/B
1.27
Dividend LFY
--
Turnover Ratio
6.62%
Amplitude
10.34%
Avg Price
1.764
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
CEO: Good, Jennifer L.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top